Sarepta names Art Krieg as CSO

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Dr. Krieg joins Sarepta (SRPT) from RaNA Therapeutics where he was CEO since co-founding the company in 2011. Prior to that, he was CSO of Pfizer's Oligonucleotide Therapeutics Unit from 2008-11.

Krieg: "The recent resurgence in the field of RNA therapeutics has been due in part to the excitement around Sarepta’s exon skipping therapies and their potential for patients with Duchenne."

Shares -1.6% AH